Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2024 financial results and provide a business update.
A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
With the Pandemic Accord negotiations set to resume tomorrow for a last-ditch effort to find consensus before the deadline at the end of May, AIDS Healthcare Foundation (AHF) has described the current state of the text as 20% equity and 80% inequity....
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Accretive acquisition of select assets in Southeast and Southwest...
Jolt Health Inc. ("JOLT" and or "the Company") is pleased to announce an arms-length agreement dated April 16, 2024 to acquire intellectual property to develop transdermal delivery technology for chloroquine and...
NioCorp Developments Ltd. ("NioCorp" or the "Company") announces that it has received a preliminary, non-binding indicative financing term sheet from the Export-Import Bank of the United States ("EXIM") as part of a...
Achieves first quarter targets, increases guidance
Q1 2024 Highlights:
Free Cash Flow of $102.1 million, compared to $73.1 million for Q1 2023, primarily derived from operating cash flows and net proceeds of $38.0 million related to the sale of two...
Medical Properties Trust, Inc. (the "Company" or "MPT") today issued the following statement in response to Steward Health Care's decision to commence an in-court restructuring process under Chapter 11 of the U.S. Bankruptcy Code.
MPT has approved...
